Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

SRPT

+ Watchlist+ Portfolio

Sarepta Therapeutics, Inc.

Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$14.77
52-Week Range
$14.53 – $24.68
Market Cap
$1.56B
P/E (TTM)
726.50
EPS (TTM)
0.02
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.02
PEG Ratio
-0.09
Return on Equity
-8.05%
Return on Assets
-0.16%
Gross Margin
23.40%
Operating Margin
-0.43%
Profit Margin
-5.86%
Current Ratio
3.46
Debt/Equity
0.71
Total Debt
$1.08B
Free Cash Flow
$109.31M
Revenue Growth
-4.50%
Earnings Growth
—
Enterprise Value
$1.76B

Market Snapshot

About

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on precision genetic medicine for rare diseases. The company develops RNA-targeted therapeutics and gene therapy candidates, particularly for Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies. It has multiple approved treatments and a robust pipeline of investigational therapies.